Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer
The natural history of small cell lung cancer (SCLC) includes rapid evolution from chemosensitivity to chemoresistance, although mechanisms underlying this evolution remain obscure due to scarcity of post-relapse tissue samples. We generated circulating tumor cell (CTC)-derived xenografts (CDXs) from SCLC patients to study intratumoral heterogeneity (ITH) via single-cell RNAseq of chemo-sensitive and -resistant CDXs and patient CTCs. We found globally increased ITH including heterogeneous expression of therapeutic targets and potential resistance pathways, such as EMT, between cellular subpopulations following treatment-resistance. Similarly, serial profiling of patient CTCs directly from blood confirmed increased ITH post-relapse. These data suggest that treatment-resistance in SCLC is characterized by coexisting subpopulations of cells with heterogeneous gene expression leading to multiple, concurrent resistance mechanisms. These findings emphasize the need for clinical efforts to focus on rational combination therapies for treatment-naïve SCLC tumors to maximize initial responses and counteract the emergence of ITH and diverse resistance mechanisms.
| Errataetall: |
CommentIn: Nat Cancer. 2020 Apr;1(4):374-375. - PMID 35121967 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:1 |
|---|---|
| Enthalten in: |
Nature cancer - 1(2020) vom: 01. Apr., Seite 423-436 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Stewart, C Allison [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CDX |
|---|
| Anmerkungen: |
Date Completed 14.04.2022 Date Revised 14.02.2024 published: Print-Electronic CommentIn: Nat Cancer. 2020 Apr;1(4):374-375. - PMID 35121967 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s43018-019-0020-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320828557 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320828557 | ||
| 003 | DE-627 | ||
| 005 | 20240214232257.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s43018-019-0020-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1292.xml |
| 035 | |a (DE-627)NLM320828557 | ||
| 035 | |a (NLM)33521652 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Stewart, C Allison |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.04.2022 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Nat Cancer. 2020 Apr;1(4):374-375. - PMID 35121967 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The natural history of small cell lung cancer (SCLC) includes rapid evolution from chemosensitivity to chemoresistance, although mechanisms underlying this evolution remain obscure due to scarcity of post-relapse tissue samples. We generated circulating tumor cell (CTC)-derived xenografts (CDXs) from SCLC patients to study intratumoral heterogeneity (ITH) via single-cell RNAseq of chemo-sensitive and -resistant CDXs and patient CTCs. We found globally increased ITH including heterogeneous expression of therapeutic targets and potential resistance pathways, such as EMT, between cellular subpopulations following treatment-resistance. Similarly, serial profiling of patient CTCs directly from blood confirmed increased ITH post-relapse. These data suggest that treatment-resistance in SCLC is characterized by coexisting subpopulations of cells with heterogeneous gene expression leading to multiple, concurrent resistance mechanisms. These findings emphasize the need for clinical efforts to focus on rational combination therapies for treatment-naïve SCLC tumors to maximize initial responses and counteract the emergence of ITH and diverse resistance mechanisms | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a CDX | |
| 650 | 4 | |a CTC | |
| 650 | 4 | |a SCLC | |
| 650 | 4 | |a intratumoral heterogeneity | |
| 650 | 4 | |a single-cell RNAseq | |
| 700 | 1 | |a Gay, Carl M |e verfasserin |4 aut | |
| 700 | 1 | |a Xi, Yuanxin |e verfasserin |4 aut | |
| 700 | 1 | |a Sivajothi, Santhosh |e verfasserin |4 aut | |
| 700 | 1 | |a Sivakamasundari, V |e verfasserin |4 aut | |
| 700 | 1 | |a Fujimoto, Junya |e verfasserin |4 aut | |
| 700 | 1 | |a Bolisetty, Mohan |e verfasserin |4 aut | |
| 700 | 1 | |a Hartsfield, Patrice M |e verfasserin |4 aut | |
| 700 | 1 | |a Balasubramaniyan, Veerakumar |e verfasserin |4 aut | |
| 700 | 1 | |a Chalishazar, Milind D |e verfasserin |4 aut | |
| 700 | 1 | |a Moran, Cesar |e verfasserin |4 aut | |
| 700 | 1 | |a Kalhor, Neda |e verfasserin |4 aut | |
| 700 | 1 | |a Stewart, John |e verfasserin |4 aut | |
| 700 | 1 | |a Tran, Hai |e verfasserin |4 aut | |
| 700 | 1 | |a Swisher, Stephen G |e verfasserin |4 aut | |
| 700 | 1 | |a Roth, Jack A |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jianjun |e verfasserin |4 aut | |
| 700 | 1 | |a de Groot, John |e verfasserin |4 aut | |
| 700 | 1 | |a Glisson, Bonnie |e verfasserin |4 aut | |
| 700 | 1 | |a Oliver, Trudy G |e verfasserin |4 aut | |
| 700 | 1 | |a Heymach, John V |e verfasserin |4 aut | |
| 700 | 1 | |a Wistuba, Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Robson, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Byers, Lauren Averett |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature cancer |d 2020 |g 1(2020) vom: 01. Apr., Seite 423-436 |w (DE-627)NLM307030067 |x 2662-1347 |7 nnns |
| 773 | 1 | 8 | |g volume:1 |g year:2020 |g day:01 |g month:04 |g pages:423-436 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s43018-019-0020-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 1 |j 2020 |b 01 |c 04 |h 423-436 | ||